Compare BHP Billiton Limited (BHP) vs Biogen Inc (BIIB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BHP Billiton Limited vs Biogen Inc — how do they compare? BHP Billiton Limited trades at $90.62 (market cap $229.15B), while Biogen Inc trades at $204.1 (market cap $30.13B). The key difference: BHP Billiton Limited is far larger — about 7.6× Biogen Inc's market cap, and BHP Billiton Limited pays a 2.95% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BHP | BIIB | |
|---|---|---|
Market Cap | $229.15B | $30.13B |
Sector | Basic Materials | Health |
52-Week High | $93.15 | $216.63 |
52-Week Low | $52.14 | $128.93 |
Enterprise Value | $243.35B | $37.20B |
Dividend Yield | 2.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BHP trades at $90.38, down 0.25% on the day, with a bullish technical signal driven by moving averages. The company reported Q4 2025 EPS of $2.24, missing expectations of $2.41, but maintains strong profitability with an 18.97% net income margin. Recent news highlights labor strikes at Port Hedland iron ore operations, potentially impacting production, while institutional buying activity signals confidence.
Outlook is mixed: solid fundamentals and copper demand from AI data centers offer growth potential, but strikes and valuation concerns pose risks. Analysts are cautious with 64.52% hold ratings, reflecting balanced near-term uncertainty amid long-term resource strengths.
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BHP Billiton Limited
BHP Group Limited operates as a mining company. The Company engages in the exploration, development, production, and processing of iron ore, metallurgical coal, and copper. BHP Group serves customers worldwide.
Read more on BHP →About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →
